Receptor mechanisms in the treatment of schizophrenia

Journal of Psychopharmacology
G P Reynolds

Abstract

There remain many limitations to the treatment of schizophrenia. In addition to the poor response of negative and cognitive symptoms to antipsychotics, and the substantial proportion of poor- or non-responders, there are a variety of unpleasant and restricting side-effects of these drugs. The introduction of several 'atypical' drugs, with diminished propensity to cause extrapyramidal motor effects (EPS), has greatly improved the tolerability of antipsychotic treatments. The pharmacology of atypical antipsychotics is varied and, although dopamine D2 receptor antagonism is common to all antipsychotics, the mechanisms of a typicality are complex and not fully understood. Thus, antagonism at 5-HT2 and/or other receptors, weak dopamine receptor affinity and, most recently, partial agonism at dopamine D2 receptors, have been variously implicated. However, because EPS have diminished with improvements in drug treatment, drug-induced weight gain has emerged as a major concern, and the pharmacological basis of this problem, involving effects at 5-HT2c and perhaps other receptors, is yielding to investigation. Some drugs, notably the D2 partial agonists, can provide antipsychotic effects without the emergence of several of the seproblema...Continue Reading

References

Jan 1, 1995·Advances in Pharmacology·G P Reynolds, C Czudek
May 1, 1996·The British Journal of Psychiatry : the Journal of Mental Science·R E LitmanD Pickar
Apr 3, 1999·British Journal of Pharmacology·C ReavillT P Blackburn
Dec 1, 1999·Biological Psychiatry·A CarlssonM L Carlsson
Jan 5, 2000·European Journal of Pharmacology·J Elliott, G P Reynolds
Mar 17, 2000·Brain Research. Brain Research Reviews·J C SchwartzP Sokoloff
May 23, 2000·Lancet·M J ArranzR W Kerwin
Jun 28, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·T J RaedlerD R Weinberger
Jan 5, 2002·Journal of Clinical Psychopharmacology·F E ScheepersR S Kahn
Jun 14, 2002·European Journal of Pharmacology·Shaun JordanC Anthony Altar
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Kevin D BurrisPerry B Molinoff
Jul 3, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Fuji YokoiDean F Wong
Aug 31, 2002·The American Journal of Psychiatry·Hsien-Yuan LaneWen-Ho Chang
Jan 1, 1998·International Journal of Psychiatry in Clinical Practice·A Shah, T De

❮ Previous
Next ❯

Citations

Aug 19, 2009·Psychopharmacology·Shona L KirkGavin P Reynolds
Sep 19, 2006·BMC Pharmacology·Alexandra HamacherMatthias U Kassack
Dec 2, 2009·BMC Pharmacology·Desheng Lu, Dennis A Carson
Oct 10, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Carrie K JonesP Jeffrey Conn
Dec 18, 2013·Pharmacogenomics·Evangelia Eirini TsermpiniGeorge P Patrinos
Jan 1, 2011·Schizophrenia Research and Treatment·Fabio PanarielloAndrea de Bartolomeis
Jun 3, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Olga O YevtushenkoGavin P Reynolds
Nov 17, 2006·Expert Opinion on Investigational Drugs·Robert Kerwin
Jan 3, 2012·Metabolism: Clinical and Experimental·Subin ParkJin Pyo Hong
Jan 2, 2010·Behavioural Brain Research·Trisha A JenkinsStephen J Cooper
Nov 26, 2009·Pharmacology & Therapeutics·Gavin P Reynolds, Shona L Kirk
May 15, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·A F Y Al HadithyA J M Loonen
Apr 5, 2008·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Asmar F Al HadithyPeter N van Harten
May 28, 2011·Journal of Cellular Physiology·Fabio PanarielloAndrea de Bartolomeis
Oct 24, 2006·European Journal of Pharmacology·Julia N HeinrichTerrance H Andree
Apr 30, 2009·Neuroscience·D A De Steno, C Schmauss
Jul 25, 2006·Expert Opinion on Pharmacotherapy·Gavin P ReynoldsBeata R Godlewska
Jun 7, 2006·Current Biology : CB·Quan YuanAmita Sehgal
May 29, 2016·Progress in Neurobiology·S ButiniH Stark
Jan 23, 2008·Journal of Psychopharmacology·S SnigdhaJ C Neill
Mar 3, 2015·Natural Product Reports·Gerrit JürjensDavid A Candito
Dec 1, 2011·Therapeutic Advances in Psychopharmacology·Gavin P Reynolds
Jul 11, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Helliner S VestriW Timothy Garvey
Apr 28, 2006·Current Opinion in Psychiatry·Peter F Buckley, Nitin Shendarkar
Jun 15, 2007·Pharmacogenetics and Genomics·Lior GreenbaumBernard Lerer
Sep 5, 2015·Chemistry, an Asian Journal·Shū Kobayashi
Mar 8, 2012·Psychiatry Investigation·Gavin P Reynolds
Apr 4, 2021·Journal of Personalized Medicine·Diana Z PaderinaSvetlana A Ivanova
Dec 17, 2008·Journal of Medicinal Chemistry·Magid Abou-Gharbia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here